The FrontlineODP™ development program is funded by the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services under contract No. 75A50121C00059.
Velico is developing a novel, platform technology for manufacturing spray dried human plasma. The FrontlineODP™ system is intended to be deployed at regional blood centers that who will produce dry plasma for use by hospitals, emergency first responders and the military. Dry plasma overcomes the logistics of conventional frozen plasma and potentially extends the availability of plasma closer to the point of injury, including rural and austere settings.
FrontlineODPTM is easily reconstituted with 200 ml of sterile water for injection (SWFI), and potentially available to be used within minutes, making it practical in the prehospital settings where thawed plasma is unavailable.
Plasma transfusions are lifesaving in critical care for the treatment of many types of trauma that result in blood loss and uncontrolled hemorrhage. Uncontrolled bleeding is recognized as the leading cause of potentially preventable death among victims of trauma.† The early administration of plasma has been shown to be lifesaving for many of these patients.
† Sperry JL, et al. Prehospital Plasma during Air Medical Transport in Trauma Patients at Risk for Hemorrhagic Shock. N Engl J Med. 2018 Jul 26;379(4):315-326
If you are a blood center, hospital, investor or interested in learning more about Velico, please click the button below to submit a request.